Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

AMGN's Imdelltra slashes lung cancer death risk by 40% in Phase III, extending survival by over five months compared to chemotherapy.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Amgen AMGN announced encouraging new data from its interim analysis of the global late-stage study evaluating Imdelltra (tarlatamab-dlle) for treating patients with small cell lung cancer (SCLC ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

It sounds too simple to be true. Exercise works just as effectively as a drug to slash the risk of dying from bowel cancer, ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...